CG Oncology (NASDAQ:CGON) vs. Adhera Therapeutics (OTCMKTS:ATRX) Critical Survey

CG Oncology (NASDAQ:CGON) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for CG Oncology and Adhera Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1	2	11	0	2.71
Adhera Therapeutics	0	0	0	0	0.00

CG Oncology currently has a consensus price target of $69.00, indicating a potential upside of 12.07%. Given CG Oncology’s stronger consensus rating and higher possible upside, equities analysts plainly believe CG Oncology is more favorable than Adhera Therapeutics.

Profitability

This table compares CG Oncology and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-22.87%	-21.82%
Adhera Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares CG Oncology and Adhera Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04 million	1,286.72	-$160.99 million	($2.07)	-29.74
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	N/A

Adhera Therapeutics has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CG Oncology has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 12.37, indicating that its stock price is 1,137% more volatile than the S&P 500.

Insider and Institutional Ownership

26.6% of CG Oncology shares are held by institutional investors. 7.4% of CG Oncology shares are held by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.